Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00795093 · ClinicalTrials.gov registry record
Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 552
- Enrollment target
NCT00795093 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 552 participants.
The verdict
NCT00795093 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 552 participants
- Enrollment target
Study Summary
The purpose of this study is to describe common treatment pathways, to collect health care utilization data and to assess symptom load as well as impact of symptoms on daily life in GERD patients who are partial-responders to PPI treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 552 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00795093
The ClinicalTrials.gov registry entry for NCT00795093 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 552 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00795093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00795093 about?
NCT00795093 is a clinical study titled "Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US". The purpose of this study is to describe common treatment pathways, to collect health care utilization data and to assess symptom load as well as impact of symptoms on daily life in GERD patients who are partial-responders to PPI treatment.
What is the current status of trial NCT00795093?
This trial is currently completed. The enrollment target is 552 participants. The study started on 2008-11. Estimated completion is 2010-01.
Who is sponsoring clinical trial NCT00795093?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.